chartexchange

IBRX
ImmunityBio, Inc. Common Stock
stockNASDAQ

At CloseNov 18, 2026 3:59:57 PM EST
6.72USD+7.348%(+0.46)15,869,693
Pre-marketNov 18, 2026 9:29:30 AM EST
6.28USD+0.319%(+0.02)
After-hoursNov 18, 2026 4:56:30 PM EST
6.73USD+0.149%(+0.01)
Loading…
Loading…
Healthcare
Biotechnology
HQ
San Diego, CA, USA
Previous Close
$6.26
Beta
1.44
52-Week High
$12.43 2026-02-25
52-Week Low
$1.95 2025-12-31
SMA 50
$8.51
SMA 200
$7.97
Avg. Vol 10D
16.72M
Avg. Vol 30D
14.22M
Avg. Vol 90D
11.55M
Relative Vol
1.12
410.68M
126,083,790
0.4900%
7,960
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.

IBRX Performance
PeriodPriceDateChangeBeta
1W6.672026-11-11+0.60%-3.257
1M8.422026-10-19-20.31%0.880
3M7.722026-08-18-13.08%1.404
6M8.002026-05-18-16.13%1.157
1Y2.102025-11-18+219.52%1.440
2Y5.012024-11-18+33.93%—
5Y6.532021-11-18+2.76%2.083
IBRX Stock Summary

ImmunityBio, Inc. Common Stock (NASDAQ:IBRX) stock price today is $6.71, and today's volume is 15,869,693. IBRX is up 7.188% today. The 30 day average volume is 14.22M. IBRX market cap is $7.14B with 1.06B shares outstanding.